FR09C0028I2 - ANTAGONISTES DE GnRH MODIFIES AUX POSITIONS 5 ET 6 - Google Patents

ANTAGONISTES DE GnRH MODIFIES AUX POSITIONS 5 ET 6

Info

Publication number
FR09C0028I2
FR09C0028I2 FR09C0028C FR09C0028C FR09C0028I2 FR 09C0028 I2 FR09C0028 I2 FR 09C0028I2 FR 09C0028 C FR09C0028 C FR 09C0028C FR 09C0028 C FR09C0028 C FR 09C0028C FR 09C0028 I2 FR09C0028 I2 FR 09C0028I2
Authority
FR
France
Prior art keywords
positions
gnrh antagonists
modified gnrh
modified
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR09C0028C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferring BV
Original Assignee
Ferring BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25273352&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR09C0028(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring BV filed Critical Ferring BV
Publication of FR09C0028I1 publication Critical patent/FR09C0028I1/fr
Application granted granted Critical
Publication of FR09C0028I2 publication Critical patent/FR09C0028I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/11—Gonadotropin; related peptides
FR09C0028C 1997-04-11 2009-07-15 ANTAGONISTES DE GnRH MODIFIES AUX POSITIONS 5 ET 6 Active FR09C0028I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/837,042 US5925730A (en) 1997-04-11 1997-04-11 GnRH antagonists
PCT/US1998/007438 WO1998046634A1 (fr) 1997-04-11 1998-04-13 ANTAGONISTES DE GnRH MODIFIES AUX POSITIONS 5 ET 6

Publications (2)

Publication Number Publication Date
FR09C0028I1 FR09C0028I1 (fr) 2009-09-25
FR09C0028I2 true FR09C0028I2 (fr) 2010-06-11

Family

ID=25273352

Family Applications (1)

Application Number Title Priority Date Filing Date
FR09C0028C Active FR09C0028I2 (fr) 1997-04-11 2009-07-15 ANTAGONISTES DE GnRH MODIFIES AUX POSITIONS 5 ET 6

Country Status (37)

Country Link
US (2) US5925730A (fr)
EP (1) EP1003774B1 (fr)
JP (2) JP4249806B2 (fr)
KR (1) KR100519421B1 (fr)
CN (1) CN1230442C (fr)
AR (1) AR011217A1 (fr)
AT (1) ATE319736T1 (fr)
AU (1) AU728642B2 (fr)
BR (1) BR9808523B1 (fr)
CA (1) CA2286190C (fr)
CY (2) CY1108063T1 (fr)
CZ (1) CZ299097B6 (fr)
DE (2) DE69833751T2 (fr)
DK (1) DK1003774T3 (fr)
EE (1) EE03974B1 (fr)
ES (1) ES2260833T3 (fr)
FR (1) FR09C0028I2 (fr)
HK (1) HK1025104A1 (fr)
HR (1) HRP980197B1 (fr)
HU (1) HU224836B1 (fr)
IL (1) IL132303A0 (fr)
LU (1) LU91585I2 (fr)
MY (1) MY114811A (fr)
NL (1) NL300395I2 (fr)
NO (2) NO324991B1 (fr)
NZ (1) NZ500142A (fr)
PL (1) PL194509B1 (fr)
PT (1) PT1003774E (fr)
RU (1) RU2199549C2 (fr)
SI (1) SI1003774T1 (fr)
SK (1) SK285381B6 (fr)
TR (1) TR199902956T2 (fr)
TW (1) TW505658B (fr)
UA (1) UA58547C2 (fr)
UY (1) UY24958A1 (fr)
WO (1) WO1998046634A1 (fr)
ZA (1) ZA983062B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
US5925730A (en) * 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists
AU1590699A (en) * 1997-11-20 1999-06-15 Ortho-Mcneil Pharmaceutical, Inc. Liquid phase process for the preparation of gnrh peptides
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) * 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
IL147138A0 (en) * 2001-12-17 2002-08-14 Yeda Res & Dev Methods of and pharmaceutical compositions for modulating cell adhesion, migration and extravasation
DE20321887U1 (de) 2003-11-10 2012-01-20 Allergan, Inc. Arzneimittel umfassend niedrige Dosierungen von Desmopressin
EP1689419A4 (fr) 2003-11-10 2009-01-14 Reprise Biopharmaceutics Llc Compositions pharmaceutiques comportant de la desmopressine faiblement dosee
CN101037472B (zh) * 2006-03-14 2013-03-27 中国人民解放军军事医学科学院毒物药物研究所 具有低组胺释放作用的促黄体生成素释放激素拮抗剂
CA2648594C (fr) * 2006-04-07 2012-10-16 Merrion Research Iii Limited Forme pharmaceutique solide par voie orale contenant un activateur
JOP20090061B1 (ar) 2008-02-11 2021-08-17 Ferring Int Center Sa طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH
US20090280169A1 (en) * 2008-05-07 2009-11-12 Merrion Research Iii Limited Compositions of peptides and processes of preparation thereof
TWI480286B (zh) * 2009-02-25 2015-04-11 Merrion Res Iii Ltd 雙膦酸鹽類組合物及藥物遞送
SG175744A1 (en) 2009-04-24 2011-12-29 Polypeptide Laboratories As Method for the manufacture of degarelix
KR101795643B1 (ko) * 2009-05-01 2017-11-09 훼링 비.브이. 전립선암 치료용 조성물
TW201043221A (en) * 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
WO2011066386A1 (fr) 2009-11-25 2011-06-03 Novetide, Ltd. Procédé de production de degarelix
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
WO2011120033A1 (fr) * 2010-03-26 2011-09-29 Merrion Research Iii Limited Compositions pharmaceutiques d'inhibiteurs de facteur xa sélectifs destinées à une administration orale
EP2632934B1 (fr) 2010-10-27 2016-11-30 Ferring B.V. Procédé de fabrication de dégarélix et de ses intermédiaires
EP2447276A1 (fr) * 2010-10-27 2012-05-02 Ferring B.V. Procédé pour la fabrication du degarelix et de ses intermédiaires
EP2654772B1 (fr) 2010-12-22 2018-09-26 The Salk Institute for Biological Studies Peptides cycliques antagonistes de la corticolibérine
AU2012204213A1 (en) 2011-01-07 2013-06-13 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
WO2013104745A1 (fr) 2012-01-13 2013-07-18 Ferring Bv Composition pharmaceutique
CA2874927A1 (fr) 2012-06-01 2013-12-05 Gregoire Schwach Fabrication de degarelix
JP7211704B2 (ja) 2015-01-29 2023-01-24 ノヴォ ノルディスク アー／エス Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤
EP3390427B1 (fr) 2015-12-17 2021-08-25 Fresenius Kabi iPSUM S.r.l. Procédé de fabrication de dégarélix et de ses intermédiaires
CN107778355B (zh) * 2016-08-25 2021-04-20 成都圣诺生物制药有限公司 一种合成西曲瑞克的方法
WO2019110688A1 (fr) 2017-12-05 2019-06-13 Ferring B.V. Composition comprenant du dégarélix pour une utilisation dans le traitement du cancer du sein
CN111943960B (zh) 2019-07-29 2022-02-15 广东东阳光药业有限公司 取代的嘧啶二酮类化合物及其用途
US11332495B2 (en) 2019-09-21 2022-05-17 RK Pharma Solutions LLC Process for the preparation of Degarelix acetate and Degarelix acetate-mannitol premix
CN114456236A (zh) * 2020-11-09 2022-05-10 深圳市健翔生物制药有限公司 一种地加瑞克乙酰化杂质的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4547370A (en) * 1983-11-29 1985-10-15 The Salk Institute For Biological Studies GnRH Antagonists
US4508921A (en) * 1984-06-28 1985-04-02 Merck & Co., Inc. Process for preparation of alpha-alkyl amino acids
US4866160A (en) * 1985-04-09 1989-09-12 The Administrators Of The Tulane Educational Fund Therapeutic decapeptides
US5073624A (en) * 1985-04-09 1991-12-17 Administrators Of The Tulane Educational Fund Therapeutic decapeptides
US4800191A (en) * 1987-07-17 1989-01-24 Schally Andrew Victor LHRH antagonists
US4935491A (en) * 1987-08-24 1990-06-19 Board Of Regents, The University Of Texas System Effective antagonists of the luteinizing hormone releasing hormone which release negligible histamine
US5171835A (en) * 1988-10-21 1992-12-15 The Administrators Of The Tulane Educational Fund LHRH antagonists
US5296468A (en) * 1989-10-30 1994-03-22 The Salk Institute For Biological Studies GnRH analogs
WO1992019651A1 (fr) * 1991-04-25 1992-11-12 Romano Deghenghi Peptides antagonistes de l'hormone de liberation de la luteinostimuline
DK0683792T3 (da) * 1992-12-18 2002-01-14 Abbott Lab LHRH-antagonister med modificerede aminoacylrester i stilling 5 og 6
IL108509A0 (en) * 1993-02-22 1994-05-30 Salk Inst For Biological Studi GnRH antagonist peptides
US5506207A (en) * 1994-03-18 1996-04-09 The Salk Institute For Biological Studies GNRH antagonists XIII
US5843901A (en) * 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
US5925730A (en) * 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists

Also Published As

Publication number Publication date
CY1108063T1 (el) 2012-01-25
RU2199549C2 (ru) 2003-02-27
DE122009000033I2 (de) 2011-07-21
EE9900479A (et) 2000-06-15
UA58547C2 (uk) 2003-08-15
NL300395I1 (nl) 2009-09-01
HUP0002704A3 (en) 2003-08-28
NZ500142A (en) 2001-10-26
HUP0002704A2 (hu) 2000-12-28
DK1003774T3 (da) 2006-07-03
US6214798B1 (en) 2001-04-10
EP1003774A1 (fr) 2000-05-31
SK285381B6 (sk) 2006-12-07
AU6969898A (en) 1998-11-11
KR20010006233A (ko) 2001-01-26
WO1998046634A1 (fr) 1998-10-22
DE69833751D1 (de) 2006-05-04
JP2001523229A (ja) 2001-11-20
CZ358699A3 (cs) 2000-06-14
CY2009008I2 (el) 2012-01-25
EP1003774B1 (fr) 2006-03-08
AU728642B2 (en) 2001-01-11
BR9808523B1 (pt) 2010-02-09
JP4249806B2 (ja) 2009-04-08
TW505658B (en) 2002-10-11
MY114811A (en) 2003-01-31
SK139699A3 (en) 2000-11-07
NO994906L (no) 1999-12-13
NO2009016I1 (no) 2009-08-10
ATE319736T1 (de) 2006-03-15
JP3645255B1 (ja) 2005-05-11
NL300395I2 (nl) 2010-01-04
KR100519421B1 (ko) 2005-10-06
LU91585I2 (fr) 2009-09-17
FR09C0028I1 (fr) 2009-09-25
HRP980197B1 (en) 2002-08-31
PL336213A1 (en) 2000-06-05
CA2286190A1 (fr) 1998-10-22
PT1003774E (pt) 2006-05-31
BR9808523A (pt) 2000-05-23
CY2009008I1 (el) 2012-01-25
NO2009016I2 (no) 2014-08-25
DE69833751T2 (de) 2006-11-09
JP2005120101A (ja) 2005-05-12
ES2260833T3 (es) 2006-11-01
AR011217A1 (es) 2000-08-02
PL194509B1 (pl) 2007-06-29
NO994906D0 (no) 1999-10-08
US5925730A (en) 1999-07-20
HU224836B1 (en) 2006-03-28
CN1230442C (zh) 2005-12-07
NO324991B1 (no) 2008-01-14
HK1025104A1 (en) 2000-11-03
HRP980197A2 (en) 1999-02-28
CZ299097B6 (cs) 2008-04-23
UY24958A1 (es) 2001-03-16
SI1003774T1 (sl) 2006-08-31
CN1259959A (zh) 2000-07-12
TR199902956T2 (xx) 2000-08-21
EE03974B1 (et) 2003-02-17
CA2286190C (fr) 2007-01-09
ZA983062B (en) 1998-10-20
IL132303A0 (en) 2001-03-19
DE122009000033I1 (de) 2009-09-17

Similar Documents

Publication Publication Date Title
FR09C0028I2 (fr) ANTAGONISTES DE GnRH MODIFIES AUX POSITIONS 5 ET 6
DE59713038D1 (de) Streptavidinmuteine
DE69823876D1 (de) Induktives bauelement und induktive bauelementanordnung
ID18003A (id) Antagonis muskarinik
DE69735349D1 (de) Graben-dmos-transistor mit leichtdotierter wanne
PT805813E (pt) Antagonistas de vasopressina triciclicos
DE59608953D1 (de) Kugelgelenk
DE59701856D1 (de) Kugelgelenk
DE59607268D1 (de) Kugelgelenk
ID24669A (id) Turunan-turunan dolastatin 15
DE69903961T2 (de) Muscarinagonisten und antagonisten
DE59711146D1 (de) Cpkd-karosserie
DE29704875U1 (de) Joystick-Anordnung
NO992059D0 (no) 2-metoksyfenylpiperazinderivater
PT811593E (pt) Agentes insecticidas e acaricidas 1,4-diaril-2-fluor-2-buteno
DE29616350U1 (de) Kugelgelenk
EE04318B1 (et) Parendatud toimega LHRH antagonistid
DE29612455U1 (de) Kugelgelenk
DE69709700D1 (de) Kontrastmittel
KR970702876A (ko) 뉴로키닌 길항제(Neurokinine (tachykinine) antagonists)
DE59803982D1 (de) Kugelgelenkanordnung
BR9404585A (pt) Lata e corpo de lata
BR9602431A (pt) Rebaixador e regularizador de juntas
DE29516777U1 (de) Pannen-Hilfe-Ball
DE29616653U1 (de) Latexspray